Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Business Officer Peter Klaus Marschel
Salarius Pharmaceuticals Inc. has filed a statement of beneficial ownership with the SEC, naming Peter Klaus Marschel as the beneficial owner and Chief Business Officer. The filing is accessible via EDGAR, the SEC's system. This news brief was generated by Public Technologies using AI and is not financial advice.
Salarius Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the Securities and Exchange Commission. The filing lists Peter Klaus Marschel as the beneficial owner, serving in the role of Chief Business Officer. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001615219-25-000189), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
